Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma

• US 5,756,464 A
• Filed: 09/10/1997
• Issued: 05/26/1998
• Est. Priority Date: 05/23/1996
• Status: Expired due to Fees

• Current Assignee: Xoma Corp.
• Original Assignee: Xoma Corp.
• Inventors: Scannon, Patrick J., Wedel, Nancy
• Primary Examiner(s): Tsang, Cecilia J.
• Assistant Examiner(s): Mohamed, Abdel A.
• Application Number:
  US08/927,438
• Time in Patent Office: 258 Days
• Field of Search: 514/12, 514/21, 514/921, 530/324, 530/350, 530/829, 424/529, 424/534
• US Class Current: 424/533
• CPC Class Codes: A61K 38/1751 Bactericidal/permeability-increasing protein [BPI]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: Y10S 530/829 Blood

Abstract

Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered.

Claims

1. A method of treating a human suffering from hemorrhage due to trauma comprising the step of administering a therapeutically effective amount of a bactericidal/permeability-increasing (BPI) protein product to said human.

2. The method of claim 1 wherein the BPI protein product is an amino-terminal fragment of BPI protein having a molecular weight of about 21 kD to 25 kD.

3. The method of claim 1 wherein the BPI protein product is rBPI₂₃ or a dimeric form thereof.

4. The method of claim 1 wherein the BPI protein product is rBPI₂₁.

5. The method of claim 1 wherein the human suffering from hemorrhage due to trauma is additionally administered at least two units of packed red blood cells.